Nasser H. Hanna, MD
Dr. Nasser H. Hanna is a specialist in internal medicine with a focus on thoracic oncology. He is the Associate Division Director of the Department of Oncology, as well as the Tom and Julie Wood Family Foundation Professor of Lung Cancer Clinical Research and a Professor of Medicine in the Division of Hematology/Oncology at the Indiana University School of Medicine.
He specializes in treating patients diagnosed with thoracic cancers including lung cancer, esophageal cancer, and malignant pleural mesothelioma. He collaborates extensively with a multidisciplinary team in caring for patients, offering them a wide range of treatments including taking part in nodule review and tumor boards and working with oncologists in testing for lung cancer molecular biomarkers to ensure that each patient benefits from personalized treatments based on their unique genetic profile.[1]
Education and Career
Dr. Hanna is board-certified in Internal Medicine. He earned his undergraduate degree at Saint Louis University, then went on to the University of Missouri to study for his medical degree. After graduation, he completed a residency at the University of Iowa in Iowa City and then completed a fellowship at Indiana University Medical Center.[1]
In addition to his clinical and educational roles at Indiana University, Dr. Hanna runs a multi-disciplinary thoracic clinic at the Indianapolis VA and is a full member of the Thoracic Oncology Program’s Experimental & Developmental Therapeutics Program, a collaborative group pursuing translational research.
Research
Dr. Hanna’s research interest focuses on thoracic oncology, and specifically on managing lung cancer in all of its forms. Through his role within the Thoracic Oncology Program of the Indiana University Melvin and Bren Simon Comprehensive Cancer Center, he is actively involved in studies on areas of epidermal growth factor receptor inhibition, anti-angiogenesis, cell-cycle inhibitors, and novel chemotherapeutic agents, all of which contribute to better outcomes for patients diagnosed with thoracic cancers.[1]
Publications
- Phase II Trial of Pembrolizumab in Patients with Platinum Refractory Germ Cell Tumors: A Hoosier Cancer Research Network Study GU14-206.
Adra N; Einhorn LH; Althouse SK; Ammakkanavar NR; Musapatika D; Albany C; Vaughn D; Hanna NH; Annals of oncology: Official Journal of the European Society for Medical Oncology 2017 Oct 17 - Long-Term Survival of Good-Risk Germ Cell Tumor Patients After Postchemotherapy Retroperitoneal Lymph Node Dissection: A Comparison of BEP × 3 vs. EP × 4 and Treating Institution.
Cary C; Jacob JM; Albany C; Masterson TA; Hanna NH; Einhorn LH; Foster RS; Clinical genitourinary cancer 2017 Oct 16 - Multidisciplinary Clinic Approach Improves Overall Survival Outcomes of Patients with Metastatic Germ Cell Tumors.
Albany C; Adra N; Snavely AC; Cary C; Masterson TA; Foster RS; Kesler K; Ulbright TM; Cheng L; Chovanec M; Taza F; Ku K; Brames MJ; Hanna NH; Einhorn LH; Annals of oncology: official journal of the European Society for Medical Oncology 2017 Nov 10
